Michael Greenberg, MD
Neurology · Waldorf, MDNPI 1932192150
Payments from drug & device makers
Across 226 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$783
- Novartis$680
- Biogen$391
- Amgen$225
- AstraZeneca$219
- Sanofi$146
- plus $1K from 28 others
What the payments were for
- Speaking & faculty fees$301%
- Food & beverage$3,64999%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $783 |
| Novartis | 52 | $680 |
| Biogen | 26 | $391 |
| Amgen(2 entities) | 12 | $225 |
| AstraZeneca | 11 | $219 |
| Sanofi | 8 | $146 |
| Avanir Pharmaceuticals, Inc. | 7 | $143 |
| Teva Pharmaceuticals USA, Inc. | 6 | $110 |
| EMD Serono, Inc. | 6 | $107 |
| Lilly USA, LLC | 4 | $91 |
| Genentech USA, Inc. | 5 | $90 |
| Supernus Pharmaceuticals, Inc. | 5 | $89 |
| UCB, Inc. | 4 | $78 |
| Kyowa Kirin, Inc. | 2 | $51 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Eisai Inc. | 2 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $35 |
| Bristol Myers Squibb | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Acorda Therapeutics, Inc | 2 | $30 |
| Averitas Pharma Inc. | 1 | $29 |
| Abbott | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Pfizer | 1 | $24 |
| TG Therapeutics, Inc. | 1 | $22 |
| Argenx US, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $19 |
| CSL Behring | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Adamas Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Neurelis, Inc. | 1 | $14 |
| Banner Life Sciences, LLC | 1 | $12 |
How this compares
$3,692 in reported general payments places this provider in the 50th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dimethyl Fumarate | 20 | $36,564 |
| Glatiramer Acetate | 14 | $27,704 |
| Nurtec OdtRimegepant Sulfate | 13 | $14,891 |
| Dalfampridine ErDalfampridine | 24 | $6,179 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 21 | $5,286 |
| Ropinirole ErRopinirole Hcl | 20 | $3,888 |
| Carbamazepine ErCarbamazepine | 20 | $3,614 |
| Pregabalin | 41 | $3,035 |
| Aspirin-Dipyridamole ErAspirin/Dipyridamole | 12 | $2,914 |
| Memantine Hcl | 63 | $2,502 |
| Memantine Hcl ErMemantine Hcl | 17 | $2,389 |
| Levetiracetam | 42 | $2,133 |
| Gabapentin | 59 | $1,967 |
| Baclofen | 38 | $1,880 |
| Entacapone | 12 | $1,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $24 | $14,89113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 442 neurology providers in Maryland.
Other neurology in Waldorf
- Baljeet SethiWaldorf$99K
- Jose MasdeuBethesda$5.8M
- Ellen MowryBaltimore$5.7M
- Daniel BeckerLutherville$4.2M
- Michael PolydefkisBaltimore$4.1M
- Pavel KleinBethesda$3.2M
- Jeffrey RothsteinBaltimore$3M
- Pavan BhargavaBaltimore$2.8M
- Thomas CrawfordBaltimore$2.4M
- Nicholas MaragakisBaltimore$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.